A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 12024 participants.
Also called NCT02111564
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 12,024 participants
- Registry
-
NCT02111564 -
2014-000305-13
-
- Other papers using this trial's data
- Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
- Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belarus, Bosnia & Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, Georgia, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Mexico, Netherlands, North Macedonia, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02111564. Randomized; double masking; primary purpose prevention. Start 2014-01-07 (actual); primary completion 2018-03-06 (actual). Results posted on 2019-11-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
- Acronym
- MARINER
- Condition
- Heart Failure
- Condition
- Respiratory Insufficiency
- Condition
- Stroke Acute
- Condition
- Infectious Diseases
- Condition
- Rheumatic Diseases
- Intervention (Drug)
- Rivaroxaban, 10 mg
- Intervention (Drug)
- Rivaroxaban, 7.5 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02111564- Content hash
9c53521ec43cbd92e54370e8dd59bc920ff74d09e80e1b1312f76376f0352bcd